Shiyao Innovation (300765.SZ) subsidiary SYS6037 injection (monkeypox mRNA vaccine) has received approval for clinical trials in the United States.

According to a report from Zhitong Finance APP, Shiyao Innovation (300765.SZ) announced that its holding subsidiary, Shiyao Group JuShi Biopharmaceutical Co., Ltd. (hereinafter referred to as JuShi Biopharma), recently received notification from the U.S. Food and Drug Administration (hereinafter referred to as FDA) that the clinical trial application for SYS6037 injection (monkeypox mRNA vaccine) developed in collaboration with the Institute of Microbiology, Chinese Academy of Sciences has been approved by the FDA, allowing clinical trials to be conducted in the United States.